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OPEN Ospemifene displays broad-
spectrum synergistic interactions 
with itraconazole through potent 
interference with fungal efflux 
activities 
Hassan E. Eldesouky 1, Ehab A. Salama1, Tony R. Hazbun2,3, Abdelrahman S. Mayhoub4* & 
1,5*Mohamed N. Seleem
Azole antifungals are vital therapeutic options for treating invasive mycotic infections. However, 
the emergence of azole-resistant isolates combined with limited therapeutic options presents a 
growing challenge in medical mycology. To address this issue, we utilized microdilution checkerboard 
assays to evaluate nine stilbene compounds for their ability to interact synergistically with azole 
drugs, particularly against azole-resistant fungal isolates. Ospemifene displayed the most potent 
azole chemosensitizing activity, and its combination with itraconazole displayed broad-spectrum 
synergistic interactions against Candida albicans, Candida auris, Cryptococcus neoformans, and 
Aspergillus fumigatus (ΣFICI = 0.05–0.50). Additionally, in a Caenorhabditis elegans infection model, the 
ospemifene-itraconazole combination significantly reduced fungal CFU burdens in infected nematodes 
by ~75–96%. Nile Red efflux assays and RT-qPCR analysis suggest ospemifene interferes directly 
with fungal efflux systems, thus permitting entry of azole drugs into fungal cells. This study identifies 
ospemifene as a novel antifungal adjuvant that augments the antifungal activity of itraconazole against 
a broad range of fungal pathogens. 
Invasive mycotic infections are life-threatening medical conditions that claim the lives of more than 1.5 mil-
lion patients worldwide1,2. Invasive mycoses mainly afects immunocompromised individuals, such as HIV
patients and organ transplant recipients3,4. Te majority of invasive fungal infections are attributed to Candida, 
Cryptococcus, and Aspergillus species1. Candida species are the most common fungal pathogen that infects
humans and are associated with more than 200,000 fatalities worldwide each year5,6. In the USA, Candida species
are the fourth-leading cause of nosocomial bloodstream infections7,8. Invasive candidiasis is mainly attributed to 
fve species, C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. Krusei9,10. However, C. auris is an emerg-
ing pathogen of a global public health concern due to its unique resistance profle to multiple antifungal drugs
and associated high mortality rates (~30–70%)11,12. Recently, the U.S. Centers for Disease Control and Prevention
(CDC) has labeled C. auris as an urgent threat that requires immediate action13. Likewise, Cryptococcus species,
especially C. neoformans, are major fungal pathogens and a leading cause of death in AIDS patients, causing more
than 600,000 deaths worldwide annually14. Another medically important fungal pathogen is Aspergillus fumig-
atus which is the main cause of recalcitrant invasive aspergillosis and also is associated with devastatingly high
mortality rates (up to 95%)1. 
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Figure 1. Chemical structures of stilbene compounds. Te trans-stilbene scafold is highlighted as bold black 
bonds. 
Te high mortality rates linked to invasive mycotic infections are mainly attributed to resistance to cur-
rent antifungal drugs, lack of rapid diagnostics, and limited therapeutic options15–19. Only three main drug
classes (polyenes, echinocandins, and azoles) are available to treat systemic mycoses17. Azoles are the only
orally-bioavailable antifungal drugs that possess broad-spectrum antifungal activity with limited side efects,
especially compared to polyenes20. Tus, azoles are the most commonly prescribed antifungal drugs for treating
a wide variety of fungal infections21. Unfortunately, the extensive use of azoles has been linked to the increased
frequency of azole-resistant fungal infections22–24. 
Given the dearth of current antifungal drugs, identifying molecules capable of enhancing the antifungal activ-
ity of azole drugs, especially against resistant fungal species, is an appealing alternative drug discovery approach. 
To this efect, we previously evaluated a library of FDA-approved drugs and clinical molecules for their ability to 
re-sensitize azole-resistant C. albicans to the efect of fuconazole. Multiple stilbene derivatives such as tamoxifen,
diethylstilbestrol, and hexestrol were found able to interact synergistically with fuconazole. Consistent with our 
results, previous studies have reported tamoxifen’s ability to re-sensitize C. neoformans to the efect of azole drugs,
both in vitro and in vivo in a murine model25–27. However, the azole chemosensitizing activity of other stilbene
derivatives remains unexplored. Additionally, the interactions of stilbene derivatives with newer azoles, and their
activities against emerging multidrug-resistant fungal species such as C. auris, have not been investigated.
In this study, the antifungal activity of nine stilbene derivatives was tested, with or without fuconazole, against
an azole-resistant C. albicans isolate. Ospemifene, an oral estrogen receptor modulator, displayed the most
potent synergistic activity with fuconazole and was further explored in combination with diferent azole drugs
against a panel of fungal pathogens including C. albicans, C. glabrata, C. auris, C. neoformans, and A. fumigatus. 
Furthermore, we assessed the efect of ospemifene on the efux activity of Candida species to identify a mecha-
nism for ospemifene’s azole chemosensitizing activity. 
Results 
Fluconazole chemosensitizing activity of stilbene derivatives. In a previous study, we screened the 
Pharmakon drug library to identify novel adjuvants that would enhance fuconazole’s antifungal activity against
an azole-resistant C. albicans isolate. Our initial screen revealed three stilbene derivatives (tamoxifen, hexestrol,
and diethylstilbestrol) that were able to interact synergistically with fuconazole. Tis result encouraged us to
further evaluate other stilbene compounds for their ability to enhance the activity of azole antifungal drugs. We





   
          



























   
 





FLC Stilbenes drugs 
Alone Combined Alone Combined 
Clomiphene 
256 
2 8 2 0.26 SYN 
Tamoxifen 2 16 4 0.26 SYN 
Toremifene 2 8 2 0.26 SYN 
Hexestrol 1 8 4 0.50 SYN 
Diethylstilbestrol 1 4 2 0.50 SYN 
Ospemifene 2 >256 2 0.02 SYN 
Raloxifene 2 64 16 0.26 SYN 
Resveratrol 8 > 256 128 0.53 ADD 
cis-stilbene 2 > 256 > 256 1.01 IND 
Table 1. Efect of diferent combinations of stilbene derivatives with fuconazole (FLC) against C. albicans NR-
29448. aΣFICI (fractional inhibitory concentration index) values, rounded to the nearest two decimal places, 
were used to measure the interaction between the tested combinations. ΣFICI interpretation corresponded 
to the following defnitions: synergistic (SYN), ΣFICI ≤ 0.50; additive (ADD), ΣFICI > 0.50 and ≤ 1; and 
indiference (IND), ΣFICI > 1 and ≤ 4. 
investigated the fuconazole chemosensitizing activity of six additional stilbene compounds, namely clomiphene,
toremifene, raloxifene, ospemifene, resveratrol, and cis-stilbene (Fig. 1). As presented in Table 1, diethylstilbes-
trol and hexestrol exhibited a moderate synergistic relationship with fuconazole against C. albicans NR-29448
(ΣFICI = 0.50). Clomiphene, toremifene, tamoxifen, and raloxifene displayed more potent fuconazole chemo-
sensitizing activity (ΣFICI = 0.26). Interestingly, ospemifene exhibited the most potent synergistic interaction
with fuconazole against C. albicans NR-29448 (ΣFICI = 0.02). resveratrol displayed an additive efect when com-
bined with fuconazole (ΣFICI = 0.53) while cis-stilbene exhibited an indiferent relationship with fuconazole
against C. albicans NR-29448 (ΣFICI = 1.01). 
Effect of ospemifene on the antifungal activity of other azole drugs. As ospemifene exhibited
the most potent fuconazole chemosensitizing activity amongst the stilbene derivatives tested, ospemifene was
selected for further investigation. Te antifungal activity of ospemifene, with and without diferent azole drugs,
was evaluated against a panel of 23 fungal isolates including strains of C. albicans, C. glabrata, C. auris, C. neofor-
mans, and A. fumigatus. Ospemifene exhibited a synergistic relationship when combined with fuconazole or
voriconazole against 22% and 26% of the isolates tested, respectively (Supplementary Table 2 and Supplementary 
Table 3). However, as shown in Table 2, ospemifene exhibited broad-spectrum synergistic interactions with itra-
conazole against all tested isolates, except for C. glabrata, resulting in a reduction in the minimum inhibitory
concentration (MIC) of itraconazole by 2- to 64-fold (ΣFICI = 0.05–0.5). 
Effect of the ospemifene-itraconazole combination on the growth kinetics of Candida, 
Cryptococcus, and Aspergillus species. To confrm the broad-spectrum itraconazole chemosensitizing
activity of ospemifene, we evaluated the efect of the ospemifene-itraconazole combination on the growth kinetics
of four fungal isolates most susceptible to the drug combination. As shown in Fig. 2, the ospemifene-itraconazole
combination (at concentrations identifed from the previous microdilution checkerboard assay) signifcantly
reduced the growth of C. albicans NR-29448 (panel a), C. auris 390 (panel b), C. neoformans NR-41298 (panel
c), and A. fumigatus NR-35312 (panel d) compared to treatment with either ospemifene or itraconazole alone. 
Ospemifene interferes with fungal ABC and MFS efflux pumps. Nile red efux assays were used to
study the impact of ospemifene on the efux activity the ATP-binding cassette (ABC) and the major facilitator
superfamily (MFS) membrane transporters expressed by Candida species. ABC and MFS transporters in fungi are
known to play an important role in conferring resistance to azole antifungals28–30. As shown in Fig. 3, ospemifene,
in a concentration-dependent manner, signifcantly interfered with Nile red efux from the ABC efux-activated 
strains (SC-TAC1G980E and TWO7243) and also from the MFS efflux-activated strains (SC-MRR1P683S and 
TWO7241) compared to the untreated control. Interestingly, the ability of ospemifene to interfere with Nile red
efux was found to be more signifcant than clorgyline, a known fungal efux pump inhibitor31. 
Effect of ospemifene on the transcription levels of azole resistance-related efflux genes. Te
efect of ospemifene on the mRNA levels of genes related to efux pump expression (namely, CDR1, CDR2, and
MDR1) was investigated using RT-qPCR. As shown in Fig. 4, ospemifene treatment at only 1 µg/ml, resulted in
a signifcant increase (by 3-fold) in the mRNA levels of CDR1 relative to the untreated control. However, a sig-
nifcant increase (by 2.6-fold) in the transcription level of CDR2 was only observed at a higher concentration of
ospemifene (20 µg/ml). Additionally, a statistically insignifcant increase (~1.5-fold) in the expression level of the 
MFS efux gene MDR1 was observed with ospemifene treatment at 20 µg/ml. 
The ospemifene-itraconazole combination reduces fungal burden in infected Caenorhabditis
elegans. To further support our in vitro results, the azole chemosensitizing activity of ospemifene was inves-
tigated in a C. elegans infection model. First, we assessed the toxicity of ospemifene in non-infected C. elegans
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Alone Combined Alone Combined 
C. albicans SC5314 0.125 0.0312 
>256 
2 0.26 SYN 
C. albicans NR-29448 4* 0.0625 8 0.05 SYN 
C. albicans NR-29437 0.5 0.06 4 0.14 SYN 
C. albicans ATCC MYA-573 0.5 0.25 1 0.50 SYN 
C. albicans TWO7241 0.5 0.125 0.5 0.25 SYN 
C. albicans TWO7243 1* 0.5 1 0.50 SYN 
C. albicans SC-TAC1G980E 0.5 0.25 1 0.50 SYN 
C. albicans SC-MRR1P683S 0.25 0.062 4 0.26 SYN 
C. glabrata ATCC 66032 0.5 0.5 4 1.02 IND 
C. glabrata ATCC MYA-2950 0.5 0.5 4 1.02 IND 
C. glabrata ATCC 2001 0.5 0.5 4 1.02 IND 
C. glabrata HM-1123 0.5 0.5 4 1.02 IND 
C. auris 385 1* 0.25 4 0.27 SYN 
C. auris 386 0.5 0.125 4 0.27 SYN 
C. auris 388 1* 0.25 4 0.27 SYN 
C. auris 389 1* 0.25 4 0.27 SYN 
C. auris 390 1* 0.125 4 0.14 SYN 
C. neoformans NR-41291 0.25 0.062 4 0.26 SYN 
C. neoformans NR-41295 0.5 0.25 1 0.50 SYN 
C. neoformans NR-41298 0.5 0.125 2 0.26 SYN 
A. fumigatus NR-35304 0.5 0.25 0.5 0.50 SYN 
A. fumigatus NR-35312 0.5 0.25 2 0.50 SYN 
A. fumigatus NR-35302 0.5 0.25 1 0.50 SYN 
Table 2. Efect of ospemifene-itraconazole (ITC) combination against diferent fungal strains. aΣFICI 
(fractional inhibitory concentration index) values, rounded to the nearest two decimal places, were used to 
measure the interaction between the tested combinations. ΣFICI interpretation corresponded to the following 
defnitions: synergistic (SYN), ΣFICI ≤ 0.50; additive (ADD), ΣFICI > 0.50 and ≤1; and indiference (IND), 
ΣFICI > 1 and ≤ 4. *Indicates itraconazole resistance. MIC values of ≥ 1 µg/ml and > 2 µg/ml were selected as 
tentative itraconazole resistance breakpoints against yeast-like pathogens and molds, respectively52,53. 
nematodes and found that ospemifene can be used safely at concentrations up to 40µg/ml (Supplementary Fig. 1).
Next, a subtoxic concentration of ospemifene (5 µg/ml) was used in combination with itraconazole (1 µg/ml) to
treat C. elegans nematodes infected with either C. albicans, C. auris, C. neoformans, or A. fumigatus. As shown in 
Fig. 5, the combination of ospemifene and itraconazole was able to signifcantly reduce the mean fungal CFU by 
~75%, 96%, 82%, and 88% in nematodes infected with either C. albicans NR-29448 (Fig. 5a), C. auris 390 (Fig. 5b),
C. neoformans NR-41298 (Fig. 5c), and A. fumigatus NR-35312 (Fig. 5d), respectively. However, itraconazole
alone, at 1 µg/ml, was able to reduce fungal burden by ~39%, 71%, 60%, and 56% against C. albicans NR-29448, C.
auris 390, C. neoformans NR-41298, and A. fumigatus NR-35312, respectively. As expected, ospemifene alone, at 
5 µg/ml, failed to reduce fungal CFU in the infected nematodes against all four fungal strains tested. 
Discussion 
Azole antifungals are vital therapeutics for the treatment of systemic fungal infections. Unfortunately, the emer-
gence of clinical fungal isolates exhibiting resistance to azole antifungals has limited their efectiveness. To amelio-
rate this challenge, we were interested in exploring new adjuvants capable of enhancing or restoring the antifungal
activity of azole antifungals, especially against azole-resistant fungal pathogens. To this end, we investigated the
azole chemosensitizing activity of nine stilbene compounds. Microdilution checkerboard assays revealed prom-
inent fuconazole chemosensitizing activity was only achieved by trans-stilbene derivatives, suggesting that the
trans-stilbene confguration is important for the fuconazole chemosensitizing efect observed. Te absence of
any detectable fuconazole chemosensitizing activity for compounds possessing the cis-stilbene structure fur-
ther strengthens the premise that the trans-confguration is critical for the fuconazole chemosensitizing activity 
observed with stilbene derivatives. 
Notably, the fluconazole chemosensitizing activity of ospemifene was found to be superior to the other
pharmacologically-related estrogen receptor antagonists. Terefore, ospemifene was evaluated further to gauge its
spectrum of azole chemosensitizing activity against a panel of clinically-relevant fungal pathogens. Interestingly, 
the ospemifene-itraconazole combination displayed broad-spectrum synergistic activity against strains of C. albi-
cans, multidrug-resistant C. auris, C. neoformans, and A. fumigatus. Importantly, ospemifene (at 4 µg/ml) was
able to sensitize multidrug-resistant C. auris to the antifungal efect of itraconazole (reducing its MIC by 4- to
8-fold). Te synergistic relationship between ospemifene and itraconazole was further validated in vivo in a C. 
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Figure 2. Efect of the ospemifene-itraconazole combination on the growth kinetics of diferent fungal 
species. Overnight cultures of fungal isolates were diluted to 0.5–2.5 × 103 CFU/ml in RPMI 1640 medium. 
Cells were treated with ospemifene, itraconazole (ITC), or a combination of the two drugs at the indicated 
concentrations. Cells were incubated at 35 °C for 48–72 h, and OD595 values were measured at diferent time 
points (0, 6, 12, 18, 24, 36 and 48 h). *Indicates statistical signifcance relative to the treated control while (#) 
indicates statistical signifcance (P < 0.05) relative to individual treatments with ospemifene or itraconazole. Te 
statistical signifcance was determined by multiple t-tests using the Holm-Sidak statistical method for multiple 
comparisons. 
Figure 3. Efect of ospemifene on Nile red efux by diferent efux hyperactive Candida strains. Efect 
of ospemifene on Nile red efux in ABC-efux hyperactive C. albicans strains (a) SC-TAC1G980E and (b)
TWO7243, and MFS efux hyperactive C. albicans strains (c) SC-MRR1P683S and (d) TWO7241. Energy-
depleted cells were loaded with Nile red (7.5 µM) and were subsequently treated with ospemifene (2 and 8 µg/
ml) or clorgyline (16 µg/ml). Efux was initiated by adding glucose (40 mM) to all treatment groups. Te Nile 
red fuorescence intensity was then monitored over 10 minutes and is expressed as the percentage of change 
in the fuorescence intensity. *Indicates a statistically signifcant diference in the fuorescence intensity of the 
treated cells relative to the untreated control (P < 0.05), as determined by multiple t-tests using the Holm-Sidak 
test for multiple comparisons. 
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Figure 4. Efect of ospemifene on the expression of azole resistance-related efux genes. C. albicans SC5314 
was treated with either DMSO or ospemifene (1, 10, 20 µg/ml) for 3 h in RPMI 1640 and then harvested. 
Te expression of (a) CDR1, (b) CDR2, and (c) MDR1 was determined by quantitative RT-PCR. Bars display 
the mean fold-change for ospemifene-treated cells relative to untreated cells. Error bars represent standard 
deviation values from three biological replicates. *Indicates a statistically signifcant diference between the 
ospemifene treatment relative to the untreated control (P < 0.05), as determined by multiple t-tests using the 
Holm-Sidak test for multiple comparisons. 
elegans infection model. Ospemifene, at only 5 µg/ml, synergistically interacted with itraconazole to signifcantly 
reduce the burden of C. albicans, C. auris, C. neoformans, and A. fumigatus in infected nematodes. It should be
noted that itraconazole is known to exert a fungistatic activity against yeast-like pathogens and a fungicidal efect
against molds32. Our data indicate that ospemifene didn’t alter the fungistatic nature of itraconazole against the
yeast pathogens C. albicans and C. auris. However, the ospemifene-itraconazole combination exhibited fungicidal
activity (~4-log reduction in CFU) against C. neoformans (Supplementary Fig. 2). Tis observation suggests a
potential clinical signifcance of ospemifene as an adjunct therapy for treating cryptococcal infections, espe-
cially in immunocompromised patients where fungicidal drugs are desperately needed. However, further in vivo
assessment in other animal models is required to evaluate ospemifene as a potential adjuvant with azoles in the
treatment of fungal infections.
It is important to note that estrogen receptor modulators have been reported to possess intrinsic antifungal
activities and also been shown to interact synergistically with fuconazole27,33. Te antifungal activity of estrogen 
receptor compounds is believed to be mediated through interference with the fungal calcineurin pathway26,33. Te
existence of an alkylamino group attached to the aromatic system of the triphenylethylene core was reported to
be essential for the calcineurin inhibitory activities of estrogen receptor modulators34. However, ospemifene lacks
this feature and thus its azole chemosensitizing activity is unlikely to be mediated by the interference of the cal-
cineurin pathway. To this end, we observed that ospemifene is capable of sensitizing efux-hyperactive Candida
strains (SC-TAC1G980E, TWO7243, SC-MRR1P683S, and TWO7241) to the antifungal efect of itraconazole. Strains
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Figure 5. In vivo efcacy of the ospemifene-itraconazole combination in reducing fungal burden in infected C.
elegans. C. elegans strain AU37 genotype [glp-4(bn2) I; sek-1(km4) X], was infected with (a) C. albicans NR-29448,
(b) C. auris 390, (c) C. neoformans NR-41298, or (d) A. fumigatus NR-35312, using an inoculum size of ~5 × 107 
CFU/ml for three hours at room temperature. Infected nematodes were washed with PBS and then treated with
the ospemifene (5µg/ml)-itraconazole (1µg/ml) combination at the respective concentration. Treatment with PBS,
ospemifene, or itraconazole (ITC) alone served as controls. Afer 24h of treatment, worms were lysed to determine
the fungal burden (CFU/worm). *Indicates a statistically signifcant diference between each treatment compared
to the untreated control (P<0.05). (#) indicates a statistically signifcant diference between the ospemifene-
itraconazole combination relative to treatment with either ospemifene or itraconazole (ITC) alone (P<0.05), as
determined by a one-way ANOVA using post-hoc Dunnet’s test for multiple comparisons. 
SC-TAC1G980E, TWO7243 are known to have increased mRNA levels of ABC-type membrane transporters, while
strains SC-MRR1P683S, and TWO7241 exhibit upregulated expression of MFS-type membrane transporters35–37. 
Tus, we postulated that the mechanism by which ospemifene enhanced the sensitivity of fungal species to the
efect of itraconazole was by interfering with the efux activity of fungal membrane transporters. We utilized
Nile red efux assays to examine the efect of ospemifene on the efux activity of Candida. Our results indicate
that ospemifene signifcantly hindered the efux of Nile red from several efux-hyperactive strains (irrespective
if they were ABC- or MFS-mediated). Interestingly, the efux inhibitory activity of ospemifene was found to be
superior to clorgyline, a known fungal efux pump inhibitor31. To ensure that ospemifene can interfere specif-
ically with the drug transporters pertinent to azole resistance, we conducted efux assays using recombinant
Saccharomyces cerevisiae strains overexpressing individual transporters, CDR1, CDR2, or MDR1, from the human
pathogen Candida albicans31,38. Further corroborating our previous results, ospemifene treatment resulted in
a signifcant increase in Nile red fuorescence intensity in all recombinant strains compared to the untreated
control (Supplementary Fig. 3). We also observed that ospemifene treatment increased the mRNA expression
levels of azole resistance-related efux genes, particularly the ABC efux gene CDR1, suggesting that ospemifene 
may interfere directly with fungal efux function. Similar increases in the expression levels of efux genes were
observed with clorgyline, a known broad-spectrum efux inhibitor (Supplementary Fig. 4)31. Of note, milbe-
mycin oxime, another known fungal efux pump inhibitor, was reported to induce the expression of MFS efux
transporters in C. albicans39. Tese fndings suggest that ospemifene may directly interfere with the efux of azole
drugs probably by acting as a more favorable substrate for efux than azoles.
It should be mentioned that the clinical signifcance of ospemifene as a potential antifungal adjuvant therapy 
stems from its ability to exert a broad-spectrum chemosensitizing activity at clinically-applicable concentrations. 
According to a report issued by European Medicines Agency, ospemifene was shown to achieve a maximum
human serum concentration of 2µM (0.785µg/ml) and up to 24µg/ml in the intestinal tract at normally indicated
dosing40. As presented in Table 2, except for C. glabrata, ospemifene was able to sensitize all fungal isolates tested 
to itraconazole at concentrations that can be easily achieved in the human gut, while ~37% of isolates (seven
strains) were sensitized at concentrations ≤1 µg/ml, which is close to ospemifene’s maximum serum concentra-
tion. Tese results are suggestive of the potential of repurposing ospemifene as an adjunct therapy for controlling 
invasive fungal infections, especially in intestinal mycoses. Of note, serious negative complications such as endo-
metrium cancer and thromboembolic efects have been reported with long-term use of estrogen modulating
therapeutics41. However, ospemifene represents a new class of selective estrogen receptor modulators that was
shown to be well-tolerated and the undesired efects on the endometrium or blood coagulation were not reported
even with long-term use41. 














   
 
 




    
 
   
 
    









   
 
 
            
   
 
  





In conclusion, this study presents trans-stilbene derivatives as potential adjuvants to enhance the antifun-
gal activity of azole drugs. A preliminary Structural-Activity-Relationship (SAR) analysis of stilbene deriva-
tives revealed that the trans-confguration of the stilbene scafold is vital for azole chemosensitizing activity.
Ospemifene was found to be the most efective azole chemosensitizing agent and exhibited a broad-spectrum
synergistic relationship with itraconazole against multiple fungal species both in vitro and in a C. elegans
infection model. More importantly, the ospemifene-itraconazole combination was efective against emerging
multidrug-resistant C. auris isolates and exerted a fungicidal efect against C. neoformans. Our preliminary mech-
anistic studies indicate ospemifene is a potent inhibitor of fungal efux pumps, which may explain ospemifene’s
ability to enhance the antifungal activity of azole drugs. 
Materials and methods 
Fungal strains and culture reagents. Sources and descriptions of the fungal strains used in this study are
provided in Supplementary Table 1. Yeast extract-peptone-dextrose (YPD) agar and broth were purchased from
Becton and Dickinson Company (Franklin Lakes, NJ). 3-(N-Morpholino) propanesulfonic acid (MOPS) was
purchased from Sigma-Aldrich (St. Louis, MO). RPMI 1640 powder, supplemented with glutamine and lacking
NaHCO3, was obtained from Termo Fisher Scientifc (Waltham, MA). 
Chemicals and drugs. Clorgyline, clomiphene, toremifene, tamoxifen, raloxifene, and ospemifene
were obtained from Cayman Chemicals (Ann Arbor, MI). Fluconazole was purchased from Fisher Scientifc
(Pittsburgh, PA). Hexestrol, 2-deoxyglucose, and cis-stilbene were purchased from Alfa Aesar (Tewksbury, MA). 
Nile red, itraconazole, voriconazole, and resveratrol were purchased from TCI America (Portland, OR). Glucose 
and diethylstilbestrol were purchased from Sigma-Aldrich (St. Louis, MO). Gentamicin sulfate was obtained from
Chem-Impex International Inc. (Wood Dale, IL). 
Microdilution checkerboard assays. Te interaction between stilbene derivatives and azole drugs was
investigated using standard broth microdilution checkerboard assays, following previously reported proto-
cols42–44. Te fractional inhibitory concentration index (ΣFICI) was used to assess the relationship between the
combination of azole drugs with each stilbene derivative. Synergistic (SYN) interactions were recorded when
ΣFICI values were ≤0.50, additive (ADD) interactions were recorded for ΣFICI values >0.50 and ≤1, while
indiference (IND) was recorded for ΣFICI values >1 and ≤439. 
Growth kinetics. Te impact of the ospemifene-itraconazole combination on the growth kinetics of C. albi-
cans NR-29448, C. auris 390, C. neoformans NR-41298, and A. fumigatus NR-35312 was evaluated by turbidity
measurement (using a spectrophotometer) as previously described45. Briefy, overnight cultures of the tested iso-
lates were adjusted to 0.5–2.5 × 103 CFU/ml in RPMI 1640 medium and incubated with ospemifene/itraconazole
at concentrations selected based on the checkerboard results. Drug-free medium served as the untreated control. 
Te fungal cultures were incubated at 35 °C and the optical densities (OD) were measured at 595 nm (OD595) at
diferent time points (0, 6, 12, 18, 24, and 48 h). 
Nile red efflux assay. Te impact of ospemifene as a potential fungal efux pump inhibitor was investi-
gated using the Nile red efux assay, as previously described46–48. Briefy, exponentially grown yeast cells were
incubated for 2 h at 35 °C using a rotating shaker (at 180 rpm) to induce starvation. Energy depleted cells were
kept overnight on ice. Cells were then treated with Nile red (7.5 µM) for 30 minutes. Nile red-loaded cells were
washed twice with PBS to remove the unbound dye. Nile red-stained cells were then transferred to 96-well plates 
containing serial dilutions of ospemifene or clorgyline (as a positive control). Drug-free wells served as negative
control. Nile red efux was initiated by adding glucose (40 mM) and the fuorescence intensity was measured at
485/528 nm using a SpectraMax i3x microplate reader (Molecular Devices, CA). Detection of the fuorescence
intensity was started 15 seconds afer glucose addition (T0), and Nile red fuorescence intensity was expressed as
the percentage of change in the fuorescence intensity relative to the T0 intensity. 
Transcriptional analysis of azole resistance-associated efflux genes. Te efect of ospemifene on
the mRNA expression of CDR1, CDR2, and MDR1 was evaluated using RT-qPCR and the gene expression was
calculated using the 2−ΔΔCt method, as previously described49. Briefy, wild-type C. albicans SC5314 was grown
overnight in YPD broth at 35 °C and then back-diluted to an OD600 of 0.1 in YPD. Te cultures were treated with 
subinhibitory concentrations of ospemifene (0, 1, 10, and 20 µg/ml) and incubated for 3 h at 35 °C. Cells were
subsequently collected by centrifugation, RNA was isolated using an Ambion Ribopure yeast kit and cDNA was
synthesized using the SuperScript III First-Strand kit (Invitrogen), following the manufacturer’s guidelines. Te
primers used in this study are provided in Supplementary Table 4. Expression was internally normalized to ACT1
and compared to the untreated control. 
Caenorhabditis elegans assay. We utilized the C. elegans infection model to test whether ospemifene
can potentiate the antifungal activity of itraconazole in vivo, following previously reported protocols50,51. Briefy, 
synchronized worms [strain AU37 genotype glp-4(bn2) I; sek-1(km4) X] at L4 phase were infected with ~1 × 106 
CFU/ml of the fungal suspension for 3 h at room temperature. Infected nematodes were washed at least fve times
with PBS to remove the non-ingested yeast cells. Te infected nematodes were subsequently treated with DMSO 
(1%), ospemifene (5 µg/ml), itraconazole (1 µg/ml), or a combination of both drugs (all test agents were evaluated
in triplicates). Treated worms were incubated at 25 °C for 24 h and were inspected microscopically to confrm
viability. C. elegans homogenates were prepared by vortexing treated worms with silicon carbide beads for two
minutes. Te homogenates were serially diluted in PBS and plated over YPD agar plates containing gentamicin
(100 g/ml). Plates were incubated for 24 h at 35 °C before CFU per worm was determined. 
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Statistical analyses. All experiments were conducted using triplicate samples for each test agent. Te sta-
tistical analysis was performed using GraphPad Prism 6.0 (Graph Pad Sofware, La Jolla, CA, USA). Te treated
groups were compared to control groups using one-way ANOVA, and P < 0.05 was considered statistically sig-
nifcant. For Nile red efux assays, multiple t-tests, using the Holm-Sidak method, were used to assess multiple
comparisons between the tested groups. 
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